JP7114575B2 - Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ - Google Patents

Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ Download PDF

Info

Publication number
JP7114575B2
JP7114575B2 JP2019515203A JP2019515203A JP7114575B2 JP 7114575 B2 JP7114575 B2 JP 7114575B2 JP 2019515203 A JP2019515203 A JP 2019515203A JP 2019515203 A JP2019515203 A JP 2019515203A JP 7114575 B2 JP7114575 B2 JP 7114575B2
Authority
JP
Japan
Prior art keywords
compound
kras
inhibitor
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532051A5 (enExample
JP2019532051A (ja
Inventor
カポニーロ，ジョルダーノ
ジョン メイヤー，マシュー
クック，ヴェセリーナ
スチュアート，ダリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019532051A publication Critical patent/JP2019532051A/ja
Publication of JP2019532051A5 publication Critical patent/JP2019532051A5/ja
Application granted granted Critical
Publication of JP7114575B2 publication Critical patent/JP7114575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019515203A 2016-09-19 2017-09-18 Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ Active JP7114575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396504P 2016-09-19 2016-09-19
US62/396,504 2016-09-19
PCT/IB2017/055641 WO2018051306A1 (en) 2016-09-19 2017-09-18 Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Publications (3)

Publication Number Publication Date
JP2019532051A JP2019532051A (ja) 2019-11-07
JP2019532051A5 JP2019532051A5 (enExample) 2020-10-22
JP7114575B2 true JP7114575B2 (ja) 2022-08-08

Family

ID=60009675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515203A Active JP7114575B2 (ja) 2016-09-19 2017-09-18 Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ

Country Status (12)

Country Link
US (2) US10973829B2 (enExample)
EP (1) EP3515446B1 (enExample)
JP (1) JP7114575B2 (enExample)
KR (1) KR102341660B1 (enExample)
CN (1) CN109715163B (enExample)
AU (1) AU2017329090B9 (enExample)
CA (1) CA3037456A1 (enExample)
CL (1) CL2019000681A1 (enExample)
ES (1) ES2974991T3 (enExample)
IL (1) IL264931B (enExample)
MX (1) MX386413B (enExample)
WO (1) WO2018051306A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
KR20200138303A (ko) * 2018-03-30 2020-12-09 노파르티스 아게 다브라페닙, 트라메티닙 및 erk 저해제를 포함하는 삼중 약제학적 조합물
EP3849536A4 (en) * 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
AU2020315388A1 (en) * 2019-07-15 2022-02-17 Memorial Sloan Kettering Cancer Center Methods useful in treating cancers harboring a KRAS or HRAS mutation or amplification
CA3158530A1 (en) 2019-10-24 2021-04-29 Stephen W. Kaldor Inhibitors of raf kinases
US20230226030A1 (en) * 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
AU2021225491A1 (en) * 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
US20240000789A1 (en) * 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor
WO2022074599A1 (en) * 2020-10-08 2022-04-14 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
WO2022074600A1 (en) * 2020-10-08 2022-04-14 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
JP2025526729A (ja) * 2022-08-10 2025-08-15 ノバルティス アーゲー ナポラフェニブを含む非晶質固体分散体
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151616A1 (en) 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015066188A1 (en) 2013-11-01 2015-05-07 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU4618497A (en) 1996-08-27 1998-03-19 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
ES2187473T3 (es) 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
WO2001021598A1 (en) 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
IL149150A0 (en) 1999-11-22 2002-12-01 Smithkline Beecham Plc 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
AU2001232809A1 (en) 2000-01-18 2001-07-31 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
WO2001052845A1 (en) 2000-01-18 2001-07-26 Vertex Pharmaceuticals Incorpoated Gyrase inhibitors and uses thereof
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
AU2001235838A1 (en) 2000-03-06 2001-09-17 Smithkline Beecham Plc Imidazol derivatives as raf kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US7495018B2 (en) 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1343779B1 (en) 2000-11-20 2007-06-27 Smithkline Beecham Corporation Novel compounds
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
PL375975A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
CN1863774B (zh) 2003-10-08 2010-12-15 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005085241A1 (ja) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
WO2005121142A1 (en) 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
CA2682189C (en) 2006-04-07 2015-12-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
ES2657635T3 (es) 2006-08-08 2018-03-06 Chugai Seiyaku Kabushiki Kaisha Derivado de pirimidina como inhibidor de PI3K y uso del mismo
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
HRP20141174T1 (hr) 2007-06-27 2015-02-13 Astrazeneca Ab Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
NZ582349A (en) 2007-06-29 2012-06-29 Sunesis Pharmaceuticals Inc Heterocyclic compounds useful as raf kinase inhibitors
EP2176249A2 (en) 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH New chemical compounds
EP2178866A2 (en) 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
KR101552742B1 (ko) 2007-07-19 2015-09-11 머크 샤프 앤드 돔 코포레이션 단백질 키나제 억제제로서의 헤테로사이클릭 아미드 화합물
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
TW200916458A (en) 2007-09-05 2009-04-16 Astrazeneca Ab Heterocyclic compounds and methods of use thereof
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
CN102015686B (zh) 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2009152356A2 (en) 2008-06-11 2009-12-17 Irm Llc Compounds and compositions useful for the treatment of malaria
JP5385382B2 (ja) 2008-07-24 2014-01-08 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾール
NZ591176A (en) 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
US20110130380A1 (en) 2009-09-04 2011-06-02 Barsanti Paul A Heteroaryl Kinase Inhibitors
EP2498608A4 (en) 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
CA2785679C (en) 2009-12-28 2017-12-12 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-oxadiazole-2-carboxamide compound
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
US20130165456A1 (en) 2010-08-26 2013-06-27 Tona M. Gilmer Combination
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
BR112014004560A2 (pt) 2011-09-01 2017-04-04 Irm Llc compostos e composições como inibidores de c-kit quinase
KR20140070616A (ko) 2011-09-21 2014-06-10 셀좀 리미티드 Mtor 저해제로서의 모르폴리노 치환된 우레아 또는 카바메이트 유도체
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
ES2670667T3 (es) 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
TW201414704A (zh) 2012-07-02 2014-04-16 Biogen Idec Inc 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MY176031A (en) * 2012-08-07 2020-07-22 Array Biopharma Inc Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
LT2892535T (lt) 2012-09-04 2021-12-10 Novartis Ag Adjuvantinis vėžio gydymo būdas
EP2900666B1 (en) 2012-09-28 2020-11-04 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase c
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
CA2907704C (en) * 2013-03-21 2023-01-10 Giordano Caponigro Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
CA3240745A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3191478B1 (en) 2014-09-12 2019-05-08 Novartis AG Compounds and compositions as raf kinase inhibitors
JP6646044B2 (ja) 2014-09-12 2020-02-14 ノバルティス アーゲー キナーゼ阻害剤としての化合物および組成物
PL3319993T3 (pl) 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
WO2017037587A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
EP3340986A1 (en) * 2015-08-28 2018-07-04 Novartis AG A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
UA125436C2 (uk) * 2016-06-03 2022-03-09 Еррей Біофарма, Інк. Фармацевтичні комбінації
JP2019517549A (ja) * 2016-06-10 2019-06-24 ノバルティス アーゲー Ｃ−ｒａｆ阻害薬の治療的使用
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
WO2018107146A1 (en) 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
CN110799245B (zh) 2017-05-16 2022-08-09 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
TW202023556A (zh) 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
MX2021007477A (es) 2018-12-20 2021-08-05 Novartis Ag Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US20230226030A1 (en) 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
US20240000789A1 (en) 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151616A1 (en) 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP2016517417A (ja) 2013-03-14 2016-06-16 ノバルティス アーゲー キナーゼ阻害剤としてのビアリールアミド化合物
WO2015066188A1 (en) 2013-11-01 2015-05-07 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Expert Opin. Pharmacother.，15(5)，2014年，pp.589-592
Nature Reviews Drug Discovery，13，2014年，pp.928-942

Also Published As

Publication number Publication date
IL264931B (en) 2021-09-30
MX2019003095A (es) 2019-07-04
RU2019111662A (ru) 2020-10-19
KR20190052062A (ko) 2019-05-15
US12011449B2 (en) 2024-06-18
RU2019111662A3 (enExample) 2020-11-26
MX386413B (es) 2025-03-18
ES2974991T3 (es) 2024-07-02
CN109715163A (zh) 2019-05-03
CL2019000681A1 (es) 2019-05-17
US20190358236A1 (en) 2019-11-28
EP3515446B1 (en) 2023-12-20
US20220008426A1 (en) 2022-01-13
AU2017329090B9 (en) 2019-09-05
BR112019005046A2 (pt) 2019-06-18
WO2018051306A1 (en) 2018-03-22
US10973829B2 (en) 2021-04-13
KR102341660B1 (ko) 2021-12-23
EP3515446A1 (en) 2019-07-31
JP2019532051A (ja) 2019-11-07
CA3037456A1 (en) 2018-03-22
AU2017329090B2 (en) 2019-08-22
CN109715163B (zh) 2022-11-22
AU2017329090A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
JP7114575B2 (ja) Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
JP7520189B2 (ja) 組み合わせ療法
US11648251B2 (en) TTP phosphorylation as a biomarker in targeted therapy
TW201909920A (zh) 治療組合
US20230226030A1 (en) Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
TW202207942A (zh) 包含ｃｒａｆ抑制劑的治療組合
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
BR112019005046B1 (pt) Combinação farmacêutica, seu uso, composição farmacêutica, usos de um inibidor de craf e de um inibidor de erk, e kit
HK40004186B (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
HK40004186A (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
RU2815400C2 (ru) Комбинированная терапия
HK40086978A (zh) 包含craf抑制剂的治疗组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250